利记·sbobet(中国)-唯一官方网站

2020-10-10

First in China! Wanbang Biopharma Perphenazine Tablets Pass Generics Consistency Evaluation

Recently, Shanghai Zhaohui Pharmaceutical Co., Ltd. ("Zhaohui Pharmaceutical"), a member enterprise of Jiangsu Wanbang Biopharmaceuticals Co., Ltd. ("Wanbang Biopharma"), received the Notice on Approval of Supplementary Drug Application for Perphenazine Tablets (2 mg, 4 mg) (No.: 2020B04654, 2020B04655) from NMPA. The drug is the first of its kind in China to pass the consistency evaluation of quality and efficacy of generic drugs.



Perphenazine Tablets is indicated for the treatment of schizophrenia and severe nausea and vomiting. By September 2020, Zhaohui Pharmaceutical has invested a cumulative R&D amount of about RMB 10.6 million (not audited) for the consistency evaluation at this stage.

Perphenazine Tablets has successfully passed the generics consistency evaluation, which will help improve the product's competitiveness, enhance the product's market position and bring new market opportunities.